The presentation “Annex 1-Compliant Filling Solutions to Handle HPAPIs” explores the critical intersection of regulatory compliance, advanced engineering, and patient safety in the aseptic processing of highly potent pharmaceuticals—specifically Antibody-Drug Conjugates (ADCs). As ADCs continue to revolutionize targeted cancer therapies, their complex and sensitive nature demands filling solutions that meet the highest standards of sterility, containment, and operator protection.
This session will highlight how Annex 1-compliant machine designs ensure aseptic integrity throughout the filling process, fully aligning with the latest EU GMP guidelines. It will further examine specialized high-potent equipment configurations tailored to the unique challenges of highly potent pharmaceutical ingredients, including advanced inspection systems, zero-reject principles, a consistent hygienic design, and reliable external cleaning. Central to the discussion is the role of advanced containment strategies with isolators, which safeguard both product and personnel without compromising efficiency or flexibility.
By integrating regulatory foresight with technological innovation, these filling solutions not only meet compliance requirements but also accelerate the safe delivery of transformative therapies to patients worldwide.